Table 1.
Characteristics of patients*
| Characteristic | Total | PCV | Temozolomide | P |
|---|---|---|---|---|
| Patients | 109 | 49 (45) | 60 (55) | |
| Gender | M = 59 (54)
F = 50 (46) |
M = 29 (59)
F = 20 (41) |
M = 30 (50)
F = 30 (50) |
0.34 |
| Age** | 39.3 ± 11.16 | 38 ± 11.6 | 40.2 ± 10.7 | 0.32 |
| Range | 18–70 | 18–66 | 18–70 | |
| KPS** | 86.3 ± 10.7 | 86.7 ± 8.3 | 86 ± 12.4 | 0.67 |
| Median | 90 | 90 | 90 | |
| Range | 60–100 | 60–100 | 60–100 | |
| Extent of resection | ||||
| Biopsy | 17 (16) | 9 (18) | 8 (13) | 0.37 |
| Partial | 48 (44) | 18 (37) | 30 (50) | |
| Total | 44 (40) | 22 (45) | 22 (37) | |
| Enhancement | ||||
| Absent | 63 (58) | 35 (71.4) | 28 (46.7) | 0.01 |
| Present | 46 (42) | 14 (28.6) | 32 (53.3) | |
Abbreviation: PCV, procarbazine, CCNU, and vincristine.
*
Numbers in parentheses are percents.
**
Mean ± SD.